138 related articles for article (PubMed ID: 26890451)
1. Implementation of the 21-gene recurrence score test in the United States in 2011.
Lynch JA; Berse B; Petkov V; Filipski K; Zhou Y; Khoury MJ; Hassett M; Freedman AN
Genet Med; 2016 Oct; 18(10):982-90. PubMed ID: 26890451
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
[TBL] [Abstract][Full Text] [Related]
3. Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.
Lynch JA; Khoury MJ; Borzecki A; Cromwell J; Hayman LL; Ponte PR; Miller GA; Lathan CS
Genet Med; 2013 Aug; 15(8):630-8. PubMed ID: 23448725
[TBL] [Abstract][Full Text] [Related]
4. 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Lynch JA; Berse B; Coomer N; Kautter J
Genet Med; 2017 Oct; 19(10):1134-1143. PubMed ID: 28333918
[TBL] [Abstract][Full Text] [Related]
5. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Orucevic A; Heidel RE; Bell JL
Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
[TBL] [Abstract][Full Text] [Related]
6. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Wilson LE; Pollack CE; Greiner MA; Dinan MA
Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
[TBL] [Abstract][Full Text] [Related]
7. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
[TBL] [Abstract][Full Text] [Related]
8. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
Kimbung S; Kovács A; Bendahl PO; Malmström P; Fernö M; Hatschek T; Hedenfalk I
Mol Oncol; 2014 Feb; 8(1):119-28. PubMed ID: 24287398
[TBL] [Abstract][Full Text] [Related]
9. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Dialani V; Gaur S; Mehta TS; Venkataraman S; Fein-Zachary V; Phillips J; Brook A; Slanetz PJ
Radiology; 2016 Aug; 280(2):370-8. PubMed ID: 26937802
[TBL] [Abstract][Full Text] [Related]
11. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
12. Genomic testing in early stage invasive male breast cancer: An NCDB analysis from 2008 to 2014.
Dubrovsky E; Raymond S; Chun J; Fong A; Patel N; Guth A; Schnabel F
Breast J; 2019 May; 25(3):425-433. PubMed ID: 31025517
[TBL] [Abstract][Full Text] [Related]
13. [Factor analysis of diagnosis and surgical treatment of local regional recurrence in breast cancer patients].
Jin ZY; Lu YJ; Chen WG; Li YF; Chen XS; Shen KW
Zhonghua Wai Ke Za Zhi; 2019 May; 57(5):366-372. PubMed ID: 31091592
[No Abstract] [Full Text] [Related]
14. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
[TBL] [Abstract][Full Text] [Related]
15. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
16. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
17. Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer.
Batra A; Nixon NA; Roldan-Urgoiti G; Hannouf MB; Abedin T; Hugh J; King K; Bigras G; Steed T; Lupichuk S
Cancer Treat Res Commun; 2021; 28():100401. PubMed ID: 34091374
[TBL] [Abstract][Full Text] [Related]
18. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
[TBL] [Abstract][Full Text] [Related]
19. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
[TBL] [Abstract][Full Text] [Related]
20. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Enewold L; Geiger AM; Zujewski J; Harlan LC
Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]